Enrico Vasile

Enrico Vasile

Auto-generated profile, based on publicly available information

Enrico Vasile

Division of Medical Oncology, Pisa University Hospital, Via Roma 67, 56126 Pisa, Italy

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Digestive and Liver Disease
Verified
Journal Article
Closed access
GBGiovanni Brandi
Giovanni Brandi
MVMichela Venturi
Michela Venturi
MPmaria pantaleo
maria pantaleo
Giorgio ErcolaniGiorgio Ercolani
Giorgio Ercolani
LFLorenzo Fornaro
Lorenzo Fornaro
GAGiuseppe Aprile
Giuseppe Aprile

23 December 2015 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
OCon behalf of the GICO group (Gruppo Italiano COlangiocarcinoma)
on behalf of the GICO group (Gruppo Italiano COlangiocarcinoma)
LFLorenzo Fornaro
Lorenzo Fornaro
CVCaterina Vivaldi
Caterina Vivaldi
SCStefano Cereda
Stefano Cereda
FLFrancesco Leone
Francesco Leone
EVEnrico Vasile
Enrico Vasile
After progression to a standard first-line platinum and gemcitabine combination (GP), there is no established second-line therapy for patients with advanced biliary tract cancers (aBTC). Indeed, literature data suggest limited activity of most second-line agents evaluated so far. We collected a large retrospective series of aBTC patients treated with second-line chemotherapy after progression to a first-line GP regimen at different Italian institutions. We then pooled the data with those reported in previous studies, which were identified with a Medline search and the on-line abstract datasets of major international oncology meetings. A total of 174 patients were included in the multicenter survey: response rate (RR) with second-line chemotherapy was low (3.4 %), with median PFS and OS of 3.0 months and 6.6 months, respectively. At multivariate analysis, preserved performance status, low CA19.9 levels and absence of distant metastases were favorable prognostic factors. Data from other five presented or published series were identified, for a total of 499 patients included in the pooled analysis. The results confirmed marginal activity of second-line chemotherapy (RR: 10.2 %), with limited efficacy in unselected patient populations (median PFS: 3.1 months; median OS: 6.3 months). The current analysis highlights the limited value of second-line chemotherapy after a first-line GP combination in aBTC. While waiting for effective biologic agents in this setting, ongoing randomized trials will identify the optimal second-line chemotherapy regimen and validate prognostic factors for individual patient management.

13 March 2020 in Cancers
Verified
Journal Article
Open access
PDF file
AUAlice Usai
Alice Usai
GFGregorio Di Franco
Gregorio Di Franco
PCPatrizia Colucci
Patrizia Colucci
LPLuca Emanuele Pollina
Luca Emanuele Pollina
EVEnrico Vasile
Enrico Vasile
RVRaffa Vittoria
Raffa Vittoria
Animal “avatars” and co-clinical trials are being developed for possible use in personalized medicine in oncology. In a co-clinical trial, the cancer cells of the patient’s tumor are xenotransplanted into the animal avatar for drug efficacy studies, and the data collected in the animal trial are used to plan the best drug treatment in the patient trial. Zebrafish have recently been proposed for implementing avatar models, however the lack of a general criterion for the chemotherapy dose conversion from humans to fish is a limitation in terms of conducting co-clinical trials. Here, we validate a simple, reliant and cost-effective avatar model based on the use of zebrafish embryos. By crossing data from safety and efficacy studies, we found a basic formula for estimating the equivalent dose for use in co-clinical trials which we validated in a clinical study enrolling 24 adult patients with solid cancers (XenoZ, NCT03668418).

18 April 2016 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
CVCaterina Vivaldi
Caterina Vivaldi
CCChiara Caparello
Chiara Caparello
GMGianna Musettini
Gianna Musettini
GPGiulia Pasquini
Giulia Pasquini
SCSilvia Catanese
Silvia Catanese
EVEnrico Vasile
Enrico Vasile

1 August 2008 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PDF file
EVEnrico Vasile
Enrico Vasile
CTCarmelo Tibaldi
Carmelo Tibaldi
ACAntonio Chella
Antonio Chella
AFAlfredo Falcone
Alfredo Falcone

24 June 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Nicola SilvestrisNicola Silvestris
Nicola Silvestris
Oronzo BrunettiOronzo Brunetti
Oronzo Brunetti
ABAlessandro Bittoni
Alessandro Bittoni
ICIvana Cataldo
Ivana Cataldo
DCDomenico Cristiano Corsi
Domenico Cristiano Corsi
MRMichele Reni
Michele Reni
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in women (7%) and the sixth in men (5%) in Italy, with a life expectancy of around 5% at 5 years. From 2010, the Italian Association of Medical Oncology (AIOM) developed national guidelines for several cancers. In this report, we report a summary of clinical recommendations of diagnosis, treatment and follow-up of PDAC, which may guide physicians in their current practice. A panel of AIOM experts in upper gastrointestinal cancer malignancies discussed the available scientific evidence supporting the clinical recommendations.